Advanced melanoma-A curable disease? Implications of systemic treatment on patients' daily life

Affiliations

Comment

Kai-Martin Thoms. J Eur Acad Dermatol Venereol. 2023 May.

. 2023 May;37(5):853-854.

doi: 10.1111/jdv.19018.

¹ Department of Dermatology, Venereology and Allergology, University Medical Center Goettingen, Goettingen, Germany.

No abstract available

Comment on

Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, Heppt MV, Dücker P, Hüning S, Schulmeyer L, Schilling B, Haferkamp S, Ziemer M, Moritz RKC, Hagelstein V, Terheyden P, Posch C, Gaiser MR, Kropp P, Emmert S, Müller B, Tietze JK. Thiem A, et al. J Eur Acad Dermatol Venereol. 2023 May;37(5):884-893. doi: 10.1111/jdv.18778. Epub 2022 Dec 7. J Eur Acad Dermatol Venereol. 2023. PMID: 36433671

1. Hodi FS, Chiarion-Sileni V, Lewis KD, Grob JJ, Rutkowski P, Lao CD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol. 2022;40(16_suppl):9522-2.
1. Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019. Eur J Cancer. 2020;130:126-38.
1. Weichenthal M, Svane IM, Sekulovic LK, Mangana J, Mohr P, Marquez-Rodas I, et al. EMRseq: registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. J Clin Oncol. 2022;40(16_suppl):9540.
1. Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-97.
1. Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of ipilimumab plus nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J Clin Oncol. 2023;41(2):212-21.